1
|
Giles RH, Maskens D, Marconi L, Martinez R, Kastrati K, Castro C, Julian Mauro JC, Bick R, Hickey M, Heng DYC, Larkin J, Bex A, Jonasch E, Maclennan SJ, Jewett MA. 2022 Global patient survey: Reported experience of diagnosis, management, and burden of renal cell carcinomas. J Clin Oncol 2023. [DOI: 10.1200/jco.2023.41.6_suppl.653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/16/2023] Open
Abstract
653 Background: Kidney cancer (renal cell carcinoma, RCC) has shown a sustained increase in its global prevalence thereby presenting increasing burden to health systems, and most of all, to individual patients and their families. Little is known about the variations in the patient experience and best practices among countries. Although individual national surveys have been held, no conclusions could be drawn about country-level variation in patient experience or best practice. Here, we report on the 3rd biennial Global Patient Survey on the diagnosis, management, and burden of Renal Cell Carcinomas conducted by the International Kidney Coalition (IKCC) and involving its Affiliate Organisations worldwide in 15 languages. The aim of the survey was to improve collective understanding and to contribute toward the reduction of the burden of kidney cancer around the world. Methods: A 35-question survey on the diagnosis, management, and burden of RCC was designed by a multi-country steering committee of patient leaders to identify geographic variations in 6 key dimensions: patient education, experience and awareness, access to care and clinical trials, best practices, quality of life, and unmet psychosocial needs. EAU, ESMO, ASCO and NCCN Guidelines committees provided topics of interest to support evidence-based medicine (eg patient perspective on active surveillance, biopsies, etc) . The survey was distributed to patients with kidney cancer and their caregivers in 15 languages, through social media and IKCC’s 49 Affiliate Organizations and/or allied organizations who are not formal affiliates. It was completed online or in paper form between 26 September 2022 and 31 October 2022. At the time of this abstract submission, the survey was still open for completion. Results: We will present the top-line results of the 2022 survey for the very first time. Survey results will be analyzed using cross-tabulations by an independent third-party organization, and multi-variate analysis of predetermined variable will be performed. The full global report will be presented, as well as individual country reports where at least 100 responses were received. Conclusions: The IKCC and its global affiliates will be using the results to ensure that patients’ voices are heard. Actionable points will suggest future projects. Furthermore, individual countries can use their reports to advance their understanding of patient experiences and to drive improvements in care provision locally.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Margie Hickey
- International Kidney Cancer Coalition, Duivendrecht, Netherlands
| | | | - James Larkin
- Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - Axel Bex
- Royal Free London NHS Foundation Trust, UCL Division of Surgery and Interventional Science, London, United Kingdom
| | - Eric Jonasch
- University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | |
Collapse
|
2
|
Kastrati K, Mathies V, Kipp AP, Huebner J. Patient-reported experiences with side effects of kidney cancer therapies and corresponding information flow. J Patient Rep Outcomes 2022; 6:126. [PMID: 36525162 PMCID: PMC9758261 DOI: 10.1186/s41687-022-00533-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Accepted: 12/09/2022] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND Treatment options for metastatic renal cell carcinoma (mRCC) have improved over recent years. Various therapies for metastatic renal cell carcinoma are currently approved for first and successive lines. Having various treatment options makes it important to reflect how patients experience side effects in the real-world setting. So far, data on the side effects of these treatments have only been collected within clinical trials, and have been mostly assessed by the investigator and not as patient-reported outcomes. Our aim was to determine patient-reported experiences of side effects in the real-world setting and to evaluate the doctor-patient communication regarding side effects. Data were collected via an anonymous, voluntary online survey given to members of a support group for RCC; the questionnaire was completed by 104 mRCC patients. RESULTS 89.1% of participants were suffering from side effects of any grade. These appeared to be higher for patients treated with tyrosine kinase inhibitors compared to those treated with immune-checkpoint inhibitors (98.4% vs. 68.4%). However, information on side effects is scarce: 4.0% had never heard anything about them while only 18.8% of participants received detailed information on possible side effects. Although 85.6% of participants reported side effects to their physician, 34.6% did not encounter an improvement. Limitations of the study include the design as an online questionnaire and the small sample, consisting only of members of a support group. CONCLUSIONS Differences can be seen between patient-reported side effects within our survey and those based on clinical trials. A shift towards more patient-reported outcomes is needed. In addition, patients seeking the advice of their physician on side effects are in need of more-or better-information and support.
Collapse
Affiliation(s)
- Karin Kastrati
- grid.275559.90000 0000 8517 6224Klinik Für Innere Medizin II, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany
| | - Viktoria Mathies
- grid.275559.90000 0000 8517 6224UniversitätsTumorCentrum Jena, University Hospital Jena, Jena, Germany
| | - Anna P. Kipp
- grid.9613.d0000 0001 1939 2794Department of Nutritional Physiology, Institute of Nutritional Sciences, Friedrich Schiller University Jena, Jena, Germany
| | - Jutta Huebner
- grid.275559.90000 0000 8517 6224Klinik Für Innere Medizin II, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany
| |
Collapse
|
3
|
Kastrati K, Rajab H, Rader A, Aichner EA, Karonitsch TM, Kiener H, Aletaha D, Bonelli M, Radner H. AB0718 Immune-apheresis in patients with inflammatory myopathies, a case series. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.4108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundIdiopathic inflammatory myopathies (IIM) comprise a heterogenous group of autoimmune diseases characterised by inflammation of muscle and affection of other organs, such as lung or skin. Some cases of IIM non-responsive to conventional treatment with glucocorticoids and DMARDs require treatment escalation. There are only limited data on efficacy and safety of immune-apheresis (IA) in IIM patients.ObjectivesThis retrospective cohort study aims to determine whether IA is effective in treating therapy-refractory IIM.MethodsPatients with active IIM undergoing IA (either plasma-exchange or immunoadsorption) at the Medical University Vienna were included in this explorative study. Patient characteristics and clinical data including serum levels of creatine kinase and concomitant medication were extracted from electronic medical records. As a primary endpoint, efficacy of IA was evaluated four weeks after initiation of IA, calculating absolute and relative change of CK-values as well as changes in steroid dose. Secondary endpoints included absolute and relative changes of CK-values at week 8 and week 12.ResultsFrom 2000 to 2021 25 IIM patients treated with IA were identified, 24 could be used for further analyses. Patient characteristics at start of IA are displayed in Table 1. Subtypes of IIM included dermatomyositis (DM 54.2%), polymyositis (PM 8.3%), Overlap-Myositis (20.8%), mmune-mediated-necrotising-myositis (IMNM 8.3 %), and antisynthetase syndrome (ASS 8.3 %). The majority of patients received concomitant steroid therapy (87.5 %) and DMARD therapy (62.5 %).Table 1.Cohort descriptives:Population, n (n= female%)24 (n=19;79.2 %)Age at Baseline (years; mean [SD];)42.5 [11.5]Subtyp Myositis (%,n)-Dermatomyositis54.2 % (13)-Polymyositis8.3 % (2)-Overlap-Myositis20.8 % (5)-Immune mediated necrotising myositis8.3 % (2)-Anti-Synthetase-Syndrom8.3 % (2)Immune Apharesis within 4 weeks (number of cycles)mean: 9.54,median: 9.5,[IQR: 8; 11.5]Previous DMARDs (%,n)-Any DMARDs-Mean number of previous DMARDs amongst all 24 patients62.5% (15)-Azathioprin33.3% (8)-Methotrexat45.8% (11)-Rituximab16.7% (4)-Mycophenolat mofetil16.7% (4)-Cyclophosphamid8.3% (2)-Ciclosporin8.3% (2)-(Hydroxy)-Chloroquin20.8% (5)-Etanercept4.2% (1)-Infliximab4.2% (1)Concomitant DMARDs (%,n)-Any DMARDs62.5% (15)-Azathioprin20.8% (5)-Methotrexat20.8% (5)-Rituximab4.2% (1)-Cyclophosphamid4.2% (1)-Ciclosporin4.2% (1)-(Hydroxy)-Chloroquin8.3% (2)Concomitant Steroids % (n)87.5% (21)-Dose prednisone at Baseline (mg/day; median [IQR])25 [12.5; 50] (21)-Dose prednisone at week 4 (mg/day; median [IQR]12.5 [0; 37.5] (22)CK-level at baseline (U/ml; median [IQR])970.5 [157.5; 3795.5]Change in CK-values from baselineAbsolute changeRelative change-to week 4 (n=24)median [IQR] U/ml% [IQR]-to week 8 (n=16)304.5 [28.8;2051]49.1 [22.4; 79.3] %-to week 12 (n=15)648.5 [25.8; 3939.3]70.0 [13.6; 87.7] %559 [-7; 3988]63.8 [-5.8; 98.1] %Until week 4 significant decrease in CK-values was observed in 21/24 patients (p<0.01; Figure 1), from median 970.5 [157.5; 3795.5] to 347[63; 1010] U/ml. Median [IQR] dose reduction of steroids was 12.5 [0; 12.5] mg/day absolute and 25% [0%, 100%] relative. No differences were observed within patients of different myositis subtypes. One patient died after 4 weeks, in 15 patients IA was maintained until week 12. Significant reduction in CK-values was observed from baseline to week 8 and 12 respectively (141 [78; 460], 111 [57;338]. Median and relative changes from baseline until week 12 are displayed in Table 1.Figure 1.Individual response in CK-levels from baseline to week 12ConclusionImmune-apheresis seems an effective therapeutic option in refractory IIM, leading to decrease of CK-values and steroid dose.References[1]Lundberg IE. Expert Perspective: Management of Refractory Inflammatory Myopathy. Arthritis Rheumatol. 2021 Aug;73(8):1394-1407.Disclosure of InterestsNone declared
Collapse
|
4
|
Giles RH, Marconi L, Martinez R, Maskens D, Kastrati K, Castro C, Julian Mauro JC, Bick R, Heng DYC, Larkin J, Bex A, Jonasch E, Maclennan SJ, Jewett MA. Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results >2,000 patients in 41 countries, with focus on older patients. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.6_suppl.306] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
306 Background: Renal cell carcinoma (RCC) is increasing in global prevalence, thereby increasing burden to health systems, and most of all, to individual patients and their families. Little is known about the variations in patient experience and best practices among countries. Here, we report on the second biennial Global Patient Survey on the diagnosis, management, and burden of Renal Cell Carcinomas conducted by the International Kidney Coalition (IKCC) worldwide in 13 languages. The aim of the survey was to improve collective understanding and to contribute toward the reduction of the burden of kidney cancer around the world. Methods: A 35-question survey on the diagnosis, management, and burden of RCC was designed by a multi-country steering committee to identify geographic variations in 6 topics: patient education, experience and awareness, access to care and clinical trials, best practices, quality of life, and unmet psychosocial needs. The survey was distributed to patients with kidney cancer and their caregivers in 13 languages, through IKCC’s 46 Affiliate Organisations and social media from 29 Oct 2020 to 5 Jan 2021. Results: 2,012 responses came from 41 countries. Survey results were analysed using cross-tabulations by an independent third-party organisation. The full global report is publicly available, as well as 7 individual country reports where at least 100 responses were received. 42% reported that the likelihood of surviving their cancer beyond 5 years was not explained Just over half (51%) reported that they were involved as much as they wanted to be in developing their treatment plan. 56% experienced barriers to their treatment 41% indicated that “No one” discussed cancer clinical trials with them 31% were invited to take part in a clinical trial 45% self-reported that they were insufficiently active 50% indicated that they ‘very often’ or ‘always’ experienced disease-related anxiety. 26% ‘very often’ or ‘always’ experienced stress related to financial issues 55% indicated that they ‘very often’ or ‘always’ experienced a fear of recurrence 52% reported having talked to their doctor/healthcare professional about their concerns 48% had been offered a biopsy in the past with only 3% refusing; 47% would be willing to undergo biopsy in the future Patients aged ≤65 experienced more barriers to quality care, understood their disease less well, and experienced a longer time to diagnosis. Conclusions: The IKCC and its global affiliates will be using the results to ensure that patients’ voices are heard. Actionable points will suggest future projects. Individual countries can use their reports to advance their understanding of patient experiences and to improve local care.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - James Larkin
- Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
| | - Axel Bex
- The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Eric Jonasch
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - Michael A.S. Jewett
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| |
Collapse
|
5
|
Giles R, Maskens D, Martinez R, Kastrati K, Castro C, Julián Mauro J, Bick R, Packer M, Heng D, Larkin J, Bex A, Jonasch E, Maclennan S, Jewett M. Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from a global patient survey in 41 countries. Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)00586-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
6
|
Giles RH, Maskens D, Martinez R, Kastrati K, Castro C, Julian Mauro JC, Bick R, Packer M, Heng DYC, Larkin J, Bex A, Jonasch E, Maclennan SJ, Jewett MA. Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from the 2020 Global Patient Survey from 41 countries. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.4579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4579 Background: The sustained increased global prevalence of kidney cancer (renal cell carcinoma, RCC) has increased the burden to health systems, and most of all, to individual patients and their families. Although individual national surveys have been held, no conclusions could be drawn about country-level variation in patient experience or best practice. Here, we report on the second biennial Global Patient Survey on the diagnosis, management, and burden of RCC. Conducted by the International Kidney Cancer Coalition (IKCC) and involving its Affiliate Organizations worldwide, the survey aims to improve collective understanding and to contribute toward the reduction of the burden of kidney cancer around the world. Methods: A 35-question survey on the diagnosis, management, and burden of RCC was designed by a multi-country steering committee of patient leaders to identify geographic variations in 6 key dimensions: patient education, experience and awareness, access to care and clinical trials, best practices, quality of life, and unmet psychosocial needs. The survey was distributed in 13 languages to patients with kidney cancer and their caregivers, through IKCC’s 46 Affiliate Organisations and social media. It was completed online or in paper form between 29 Oct 2020 and 5 Jan 2021. Results: 2,012 (1,586 patients, 417 carers, 9 undisclosed) responses were recorded from 41 countries in 13 languages. Survey results were analyzed using cross-tabulations by an independent third-party organization. The full global report will be publicly available, as well as 7 individual country reports where at least 100 responses were received. 52% lacked understanding of subtype at diagnosis. 42% reported that the likelihood of surviving their cancer beyond 5 years was not explained. 51% reported that they were involved as much as they wanted to be in developing their treatment plan. 41% indicated that “No one” discussed cancer clinical trials with them. 31% were invited to take part in a clinical trial. 56% experienced barriers to their treatment. 45% self-reported that they were insufficiently physically active; 15% were completely sedentary. 50% indicated that they ‘very often’ or ‘always’ experienced disease-related anxiety. 55% indicated that they ‘very often’ or ‘always’ experienced a fear of recurrence. 52% reported having talked to their doctor/healthcare professional about their concerns. Conclusions: The IKCC and its global affiliates will use these results to ensure that patient and caregiver voices are heard and acted upon, with ultimate incorporation of these findings by much broader communities into care pathways, clinical practice, or health technology assessments. Furthermore, individual countries can use their reports to advance understanding of patient experiences and to drive improvements in providing care locally.
Collapse
Affiliation(s)
- Rachel H. Giles
- International Kidney Cancer Coalition, Duivendrecht, Netherlands
| | | | | | | | | | | | | | | | | | - James Larkin
- Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
| | - Axel Bex
- The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Eric Jonasch
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - Michael A.S. Jewett
- Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
| |
Collapse
|
7
|
Eisfeld H, Bauer F, Dubois C, Schmidt T, Kastrati K, Hochhaus A, Hübner J. Importance of and Satisfaction with Information about Their Disease in Cancer Patients. J Cancer Educ 2020; 35:403-411. [PMID: 30684231 DOI: 10.1007/s13187-019-1480-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
To learn more about information needs and satisfaction with provided information among cancer patients and whether dissatisfaction with information has any association with how therapy decisions are made. An online survey was conducted during March 2015 and January 2016 by the German non-profit patient organization "Das Lebenshaus e.V." among their members with rare solid tumors. A total of 338 records was analyzed. The majority found information on their disease important and was satisfied with the provided information. The participants were less satisfied with the information concerning management of side effects than with other aspects of information (p < .001). Support groups, lectures, and the oncologist were rated as the most helpful sources of information followed by a second opinion and media. Participants who were dissatisfied with the information more often made the decision on the treatment alone by themselves (p < .001). Our results show a high satisfaction with disease-related information among our study participants. Improvements could be made by offering more information on the management of side effects and by giving more information about support groups, reliable websites, and other helpful media.
Collapse
Affiliation(s)
- Hannah Eisfeld
- Klinik für Innere Medizin II, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany
| | - Fabienne Bauer
- Klinik für Innere Medizin II, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany
| | - Clara Dubois
- Klinik für Innere Medizin II, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany
| | - Thorsten Schmidt
- Krebszentrum Nord, CCC, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Arnold-Heller-Straße 3, Haus 14, 24105, Kiel, Germany
| | - Karin Kastrati
- Das Lebenshaus e.V. (House of Life), Untergasse 36, 61200, Wölfersheim, Germany
| | - Andreas Hochhaus
- Klinik für Innere Medizin II, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany
| | - Jutta Hübner
- Klinik für Innere Medizin II, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany.
| |
Collapse
|
8
|
Dubois C, Eisfeld H, Bauer F, Schmidt T, Kastrati K, Hochhaus A, Hübner J. Not all cancer patients with an interest in CAM are the same. Differences between patients with a CAM interest prior to the cancer diagnosis and those with first-time interest since diagnosis. Complement Ther Med 2019; 45:167-171. [DOI: 10.1016/j.ctim.2019.06.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2019] [Accepted: 06/13/2019] [Indexed: 01/02/2023] Open
|
9
|
Bauer F, Schmidt T, Eisfeld H, Dubois C, Kastrati K, Hochhaus A, Huebner J. Information needs and usage of complementary and alternative medicine in members of a German self-help group for gastrointestinal stroma tumours, sarcoma, and renal cancer. Complement Ther Med 2018; 41:105-110. [DOI: 10.1016/j.ctim.2018.09.008] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2018] [Revised: 09/09/2018] [Accepted: 09/10/2018] [Indexed: 10/28/2022] Open
|